Oligo-Fucoidan Decrease Lung Radiation Damage

Fucoidan is FDA approved and in common use for treatment of angina. These studies will advance that work to human use. Successful mitigation of lung radiation damage and heart toxicity will improve the quality of life in veterans and non-veterans who are treated for lung cancer by radiation, and may also improve cure rates of radiation therapy for lung cancer.

Inclusion Criteria:Ages Eligible for Study: 20-90 years oldMen and women undergoing radiation therapy for lung cancer，no matter the radiation therapy is for curing or for palliating.Karnofsky performance status，KPS > 70Absolute Neutrophils > 1000/mm^3Platelets > 75,000/mm^3Hematocrit > 25%.Liver and kidney function tests will be within normal rangeBaseline blood pressure will be systolic > 110 mmHg sittingExclusion Criteria:Patients who get lung cancer but no need or without the willingness of radiation therapyPatients who are taking antiHTN drugsWomen of pregnant, lactating, childbearing potential, or with the intention of becoming pregnantPatients who are presently participating in another clinical study (except for follow-up surveys for study outcomes)Patients who are judged to be ineligible for study entry by the investigator or subinvestigator